Recursion Pharmaceuticals (RXRX) is set to release critical clinical data from its TUPELO Phase 1b/2 trial of REC-4881 in FAP on Monday, December 8, 2025, via its first-ever company webinar. Given the company's decision to host a prominent webinar for this readout, despite being a highly shorted stock, it suggests potential confidence in positive data. This event could trigger significant price movement due to a potential short squeeze if the data is favorable.